Cargando…

An In Silico Approach towards the Prediction of Druglikeness Properties of Inhibitors of Plasminogen Activator Inhibitor1

Diabetic retinopathy is the leading cause of blindness worldwide. It is caused by the abnormal growth of the retinal blood vessels. Plasminogen activator inhibitor1 (PAI1) is the key growth factor and the inhibition of PAI1 can reduce the angiogenesis. In this study, currently available inhibitors a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Subramanian, Umadevi, Sivapunniyam, Ashok, Pudukadu Munusamy, Ayyasamy, Sundaram, Rajakumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279271/ https://www.ncbi.nlm.nih.gov/pubmed/25580120 http://dx.doi.org/10.1155/2014/385418

Ejemplares similares

Discovery of Potent and Selective Tricyclic Inhibitors of Bruton’s Tyrosine Kinase with Improved Druglike Properties
por: Wang, Xiaojing, et al.
Publicado: (2017)

Iterative Conversion of Cyclin Binding Groove Peptides into Druglike CDK Inhibitors with Antitumor Activity
por: Premnath, Padmavathy Nandha, et al.
Publicado: (2014)

Analysis of the uncharted, druglike property space by self-organizing maps
por: Takács, Gergely, et al.
Publicado: (2021)

Structure-Guide Design and Optimization of Potential Druglikeness Inhibitors for TGFβRI with the Pyrrolopyrimidine Scaffold
por: Meng, Dan, et al.
Publicado: (2022)

Novel, Potent, and Druglike Tetrahydroquinazoline Inhibitor That Is Highly Selective for Human Topoisomerase II α over β
por: Ortega, Jose Antonio, et al.
Publicado: (2020)

Description of Druglike Properties of Safranal and Its Chemistry behind Low Oral Exposure
por: Dogra, Ashish, et al.
Publicado: (2020)

Bioactive Coumarins and Xanthones From Calophyllum Genus and Analysis of Their Druglikeness and Toxicological Properties
por: Gómez-Verjan, J.C., et al.
Publicado: (2017)

Uniting Cheminformatics and Chemical Theory To Predict the Intrinsic Aqueous Solubility of Crystalline Druglike Molecules
por: McDonagh, James L., et al.
Publicado: (2014)

Hybrid Approach to Identifying Druglikeness Leading Compounds against COVID-19 3CL Protease
por: Aqeel, Imra, et al.
Publicado: (2022)

miDruglikeness: Subdivisional Drug-Likeness Prediction Models Using Active Ensemble Learning Strategies
por: Cai, Chenjing, et al.
Publicado: (2022)

CLC-Pred 2.0: A Freely Available Web Application for In Silico Prediction of Human Cell Line Cytotoxicity and Molecular Mechanisms of Action for Druglike Compounds
por: Lagunin, Alexey A., et al.
Publicado: (2023)

1-Oxo-3,4-dihydroisoquinoline-4-carboxamides as novel druglike inhibitors of poly(ADP-ribose) polymerase (PARP) with favourable ADME characteristics
por: Safrygin, Alexander, et al.
Publicado: (2021)

QEX: target-specific druglikeness filter enhances ligand-based virtual screening
por: Mochizuki, Masahiro, et al.
Publicado: (2018)

The effects of residual platelets in plasma on plasminogen activator inhibitor-1 and plasminogen activator inhibitor-1-related assays
por: Pieters, Marlien, et al.
Publicado: (2017)

Localization of Urokinase‐type Plasminogen Activator, Plasminogen Activator Inhibitor‐1, 2 and Plasminogen in Colon Cancer
por: Naitoh, Hiroyuki, et al.
Publicado: (1995)

Evaluating Translational Efficiency of Noncanonical Amino Acids to Inform the Design of Druglike Peptide Libraries
por: Chan, Alix I, et al.
Publicado: (2023)

Retraction: The effects of residual platelets in plasma on plasminogen activator inhibitor-1 and plasminogen activator inhibitor-1-related assays
Publicado: (2018)

Vitamin D Deficiency is Associated With Increased Plasminogen Activator Inhibitor 1/Plasminogen Activator Inhibitor 2 Ratio in Pregnancy
por: Andersen, Matilde Kanstrup, et al.
Publicado: (2023)

Prediction of aqueous intrinsic solubility of druglike molecules using Random Forest regression trained with Wiki-pS0 database
por: Avdeef, Alex
Publicado: (2020)

Functional Stability of Plasminogen Activator Inhibitor-1
por: Yasar Yildiz, Songul, et al.
Publicado: (2014)

Activators and inhibitors of the plasminogen system in Alzheimer’s disease
por: Barker, Rachel, et al.
Publicado: (2012)

Synthesis of Dihydrouracils Spiro-Fused to Pyrrolidines: Druglike Molecules Based on the 2-Arylethyl Amine Scaffold
por: Blanco-Ania, Daniel, et al.
Publicado: (2010)

The Allosteric Site on SHP2’s Protein Tyrosine Phosphatase Domain is Targetable with Druglike Small Molecules
por: Marsh-Armstrong, Brennan, et al.
Publicado: (2018)

Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiency
por: Saes, Joline L., et al.
Publicado: (2019)

Usefulness of plasminogen activator inhibitor-1 as a predictive marker of mortality in sepsis
por: Hoshino, Kota, et al.
Publicado: (2017)

Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 Levels in Patients with Acute Paraquat Intoxication
por: Seok, Su-Jin, et al.
Publicado: (2011)

Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1
por: Gong, Lihu, et al.
Publicado: (2016)

Role of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in psychological stress and depression
por: Tsai, Shih-Jen
Publicado: (2017)

Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients
por: Zuo, Yu, et al.
Publicado: (2021)

Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors
Publicado: (1987)

Plasminogen activator inhibitor type 2 in breast cancer.
por: Duggan, C., et al.
Publicado: (1997)

Does Plasminogen Activator Inhibitor-1 Drive Lymphangiogenesis?
por: Bruyère, Françoise, et al.
Publicado: (2010)

Plasminogen Activator Inhibitor-1 and Oncogenesis in the Liver Disease
por: Nam, Da-eun, et al.
Publicado: (2021)

The role of plasminogen activator inhibitor-2 in pneumococcal meningitis
por: Teske, Nina C., et al.
Publicado: (2022)

In silico docking of urokinase plasminogen activator and integrins
por: Degryse, Bernard, et al.
Publicado: (2008)

Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation
por: Gupta, Kamlesh K., et al.
Publicado: (2017)

Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.
por: Knoop, A., et al.
Publicado: (1998)

Relationship between tissue plasminogen activator, plasminogen activator inhibitor and CT image in chronic subdural hematoma.
por: Lim, D. J., et al.
Publicado: (1995)

Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482, a novel plasminogen activator inhibitor-1 inhibitor, inhibits ovarian cancer peritoneal dissemination
por: Nakatsuka, Erika, et al.
Publicado: (2017)

Tankyrase Inhibitor for Cardiac Tissue Regeneration: an In-silico Approach
por: Hosseini, Faezeh Sadat, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hre5m4mpmnh60nh4mjeua8eofn